×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at ACC.15

Amgen will present 15 abstracts including data evaluating RepathaTM (evolocumab) and Corlanor® (ivabradine), at the upcoming American College of Cardiology’s 64th Annual Scientific Session (ACC.15), being held March 14-16 in San Diego.

Follow Amgen on Twitter at twitter.com/amgen to receive news updates during ACC.15.


March 15, 2015 Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (Evolocumab) In The New England Journal of Medicine
March 14, 2015 New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
March 2, 2015 Amgen Showcases Cardiovascular Pipeline at ACC.15 With New Cholesterol-Lowering and Chronic Heart Failure Data